A phase II trial of docetaxel (Taxotere?) as second-line chemotherapy in patients with metastatic breast cancer

Abstract  The efficacy and tolerability of docetaxel 100 mg/m2 every 3 weeks as second-line chemotherapy in patients with metastatic breast cancer was investigated. In addition, the efficacy of a 3-day prophylaxis against cumul